about
PHF6 mutations in T-cell acute lymphoblastic leukemiaImproved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia.SNX10 mutations define a subgroup of human autosomal recessive osteopetrosis with variable clinical severity.Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia.EVI1 overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22.The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemiaBone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood.MicroRNA-128-3p is a novel oncomiR targeting PHF6 in T-cell acute lymphoblastic leukemia.Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international studyRole of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia.Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia.Etoposide in continuous infusion: practical recommendations for pediatric protocols.Molecular basis and clinical significance of genetic aberrations in B-cell precursor acute lymphoblastic leukemia.Novel biological insights in T-cell acute lymphoblastic leukemia.ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.Prognostic discrimination based on the EUTOS long term survival score within the international registry for chronic myeloid leukemia in children and adolescents.Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
P50
Q29394463-B8CB8A42-7228-4D3D-922A-967CCEA805AEQ33997207-B0C81697-1C3E-4E6D-8B6A-4DF58B9D2D7CQ34212680-3033E34C-E4A7-48FD-A999-1F8979B76C03Q34320437-7C69E72C-7B33-4801-838B-00D2760F268CQ34797988-E4717288-3D09-4017-A231-72945A10BCC6Q34836275-E527CB7A-DC11-4975-A8AE-C41CDFF63CCBQ35140239-876AF0CB-EA88-4743-A4D8-983BADFD64B9Q35146272-1B0E0D43-D27A-492A-B527-E067E71FC928Q35181216-9D62A320-06C8-44D5-A4B2-1DB7140C85A3Q36053792-C9B659CE-CE98-4748-9D74-CB2BA3D5F308Q36091293-E9F14DEA-EB75-47B7-BD01-39F8EF40F898Q36184960-9CD563E5-713B-4975-9BE0-8E8835878849Q36329453-33F04E9A-F1C3-4E1E-9B0B-D9D9CE6C1920Q37659087-2FBA85F3-E408-44EE-ADA6-9D8D3920954BQ37687468-75BCB03C-9769-44CD-883D-0D8E81914F6DQ37963250-B54042AE-0898-4DF0-B5D9-E077113E5557Q38535014-7C11C8A8-AAF5-4627-BD68-E0E7E9901F36Q38540267-FD0BCF64-FE14-4967-8C1B-ECAD23474AC6Q38949201-47DE20DD-16D4-46EA-B936-029C49A265C6Q40071286-FE516626-55A6-44F9-AF08-8266590557E2Q40116316-47C86683-0C49-4946-8689-2ED9E12B8137
P50
description
onderzoeker
@nl
name
Barbara De Moerloose
@ast
Barbara De Moerloose
@en
Barbara De Moerloose
@es
Barbara De Moerloose
@sl
type
label
Barbara De Moerloose
@ast
Barbara De Moerloose
@en
Barbara De Moerloose
@es
Barbara De Moerloose
@sl
prefLabel
Barbara De Moerloose
@ast
Barbara De Moerloose
@en
Barbara De Moerloose
@es
Barbara De Moerloose
@sl